Generic Name: romidepsin
Drug Class: Chemotherapy Medications
Approval Status: Approved
Generic Version Available: No
Istodax is an HDAC inhibitor approved for previously treated cutaneous and peripheral T-cell lymphoma.
Istodax is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.
Istodax is administered by intravenous infusion. It is usually given on three days of a 28-day cycle as long as a patient continues to benefit.
Common side effects include nausea, fatigue, vomiting and loss of appetite. Istodax can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential severe side effects include heart rhythm abnormalities and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Istodax may cause fetal harm if used during pregnancy.
For More Info: https://media.celgene.com/content/uploads/istodax-pi.pdf
Last Reviewed: November 29, 2018